WallStSmart

Fresenius Medical Care Corporation (FMS)vsNutex Health Inc (NUTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 2100% more annual revenue ($19.36B vs $879.95M). NUTX leads profitability with a 11.0% profit margin vs 4.9%. NUTX trades at a lower P/E of 9.9x. NUTX earns a higher WallStSmart Score of 64/100 (C+).

FMS

Buy

50

out of 100

Grade: C-

Growth: 2.7Profit: 5.0Value: 9.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.96

NUTX

Buy

64

out of 100

Grade: C+

Growth: 8.0Profit: 9.0Value: 8.3Quality: 7.0
Piotroski: 4/9Altman Z: 2.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FMSUndervalued (+69.0%)

Margin of Safety

+69.0%

Fair Value

$77.65

Current Price

$22.03

$55.62 discount

UndervaluedFair: $77.65Overvalued
NUTXUndervalued (+63.6%)

Margin of Safety

+63.6%

Fair Value

$283.22

Current Price

$135.10

$148.12 discount

UndervaluedFair: $283.22Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
11.9x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

PEG RatioValuation
0.798/10

Growing faster than its price suggests

NUTX5 strengths · Avg: 9.4/10
P/E RatioValuation
9.9x10/10

Attractively priced relative to earnings

Operating MarginProfitability
37.5%10/10

Strong operational efficiency at 37.5%

EPS GrowthGrowth
95.9%10/10

Earnings expanding 95.9% YoY

Return on EquityProfitability
27.8%9/10

Every $100 of equity generates 28 in profit

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

FMS4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Return on EquityProfitability
7.1%3/10

ROE of 7.1% — below average capital efficiency

Profit MarginProfitability
4.9%3/10

4.9% margin — thin

Revenue GrowthGrowth
-5.5%2/10

Revenue declined 5.5%

NUTX3 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Market CapQuality
$927.61M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.013/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.79 suggests the stock is reasonably priced for its growth.

Bull Case : NUTX

The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth.

Bear Case : FMS

The primary concerns for FMS are Altman Z-Score, Return on Equity, Profit Margin. Thin 4.9% margins leave little buffer for downturns.

Bear Case : NUTX

The primary concerns for NUTX are Revenue Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

NUTX carries more volatility with a beta of 2.06 — expect wider price swings.

NUTX is growing revenue faster at 2.2% — sustainability is the question.

NUTX generates stronger free cash flow (74M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NUTX scores higher overall (64/100 vs 50/100). FMS offers better value entry with a 69.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Nutex Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?